{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:37:30Z","timestamp":1777624650586,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004386","name":"Universiti Malaya","doi-asserted-by":"publisher","award":["PG007-2014B"],"award-info":[{"award-number":["PG007-2014B"]}],"id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.biopha.2018.11.010","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T05:35:36Z","timestamp":1542432936000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin"],"prefix":"10.1016","volume":"110","author":[{"given":"Mathura Subangari","family":"Dorasamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravind","family":"AB","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha","family":"Nellore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6705-2521","authenticated-orcid":false,"given":"Pooi-Fong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2018.11.010_bib0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s40265-014-0234-4","article-title":"Nivolumab: a review of its use in patients with malignant melanoma","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.biopha.2018.11.010_bib0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/exd.12402","article-title":"Expression of AID in malignant melanoma with BRAFV600E mutation","volume":"23","author":"Okura","year":"2014","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.biopha.2018.11.010_bib0015","first-page":"2045","article-title":"Nivolumab in the treatment of malignant melanoma: review of the literature","volume":"8","author":"Mashima","year":"2015","journal-title":"Oncol. Ther."},{"issue":"26","key":"10.1016\/j.biopha.2018.11.010_bib0020","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9839","key":"10.1016\/j.biopha.2018.11.010_bib0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2018.11.010_bib0030","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMcibr1013704","article-title":"Resistance to BRAF inhibition in melanomas","volume":"364","author":"Solit","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2018.11.010_bib0040","series-title":"ASCO Annual Meeting Proceedings","article-title":"The genetic landscape of clinical resistance to RAF inhibition in melanoma","author":"Van Allen","year":"2013"},{"issue":"9","key":"10.1016\/j.biopha.2018.11.010_bib0045","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.010_bib0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CCO.0b013e3283436e8c","article-title":"RAF inhibition and induction of cutaneous squamous cell carcinoma","volume":"23","author":"Robert","year":"2011","journal-title":"Curr. Opin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.010_bib0055","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-10-0181","article-title":"Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth","volume":"9","author":"Carnahan","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.010_bib0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.010_bib0065","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.010_bib0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.010_bib0075","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1021\/ml300049d","article-title":"Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973)","volume":"3","author":"Rice","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"7466","key":"10.1016\/j.biopha.2018.11.010_bib0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12441","article-title":"Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers","volume":"501","author":"Hatzivassiliou","year":"2013","journal-title":"Nature"},{"issue":"7074","key":"10.1016\/j.biopha.2018.11.010_bib0085","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2018.11.010_bib0090","first-page":"43","article-title":"MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy","volume":"10","author":"Tran","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2014.12.050","article-title":"Advances in targeted therapy for unresectable melanoma: new drugs and combinations","volume":"359","author":"Hao","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2018.11.010_bib0105","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/851387","article-title":"Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy","volume":"2015","author":"Niezgoda","year":"2015","journal-title":"Biomed Res. Int."},{"issue":"15","key":"10.1016\/j.biopha.2018.11.010_bib0110","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.7150\/jca.14835","article-title":"Dihydroorotate dehydrogenase inhibitors target c-Myc and arrest melanoma, myeloma and lymphoma cells at S-phase","volume":"8","author":"Dorasamy","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2018.11.010_bib0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.010_bib0120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.yrtph.2007.11.009","article-title":"A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development","volume":"50","author":"Robinson","year":"2008","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.010_bib0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1258\/002367793780810397","article-title":"Genetic variation within and between strains of outbred Swiss mice","volume":"27","author":"Cui","year":"1993","journal-title":"Lab. Anim."},{"issue":"11","key":"10.1016\/j.biopha.2018.11.010_bib0130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/ng1665","article-title":"The origins and uses of mouse outbred stocks","volume":"37","author":"Chia","year":"2005","journal-title":"Nat. Genet."},{"issue":"5743","key":"10.1016\/j.biopha.2018.11.010_bib0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/283157a0","article-title":"Genetic variance of laboratory outbred Swiss mice","volume":"283","author":"Rice","year":"1980","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2018.11.010_bib0140","first-page":"2317","article-title":"Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-l-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance","volume":"43","author":"Martin","year":"1983","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.010_bib0145","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.010_bib0150","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.30785","article-title":"Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival","volume":"141","author":"Liu","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0155","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1078-0432.CCR-07-1440","article-title":"The mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel","volume":"14","author":"Haass","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.010_bib0160","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-06-0084","article-title":"Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases","volume":"5","author":"Smalley","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.010_bib0165","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.010_bib0170","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.biopha.2018.11.010_bib0175","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.11.010_bib0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-642-54490-3_13","article-title":"Vemurafenib","volume":"201","author":"Garbe","year":"2014","journal-title":"Recent Results Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.010_bib0185","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest. New Drugs"},{"issue":"8","key":"10.1016\/j.biopha.2018.11.010_bib0190","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/2159-8290.CD-12-0520","article-title":"Unpicking the combination lock for mutant BRAF and RAS melanomas","volume":"3","author":"Al-Lazikani","year":"2013","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.biopha.2018.11.010_bib0200","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.2013.52.1377","article-title":"Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges","volume":"32","author":"Hu-Lieskovan","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.010_bib0205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ctrv.2012.10.006","article-title":"Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?","volume":"39","author":"Nijenhuis","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2018.11.010_bib0210","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/307059","article-title":"Combination therapies for the treatment of advanced melanoma: a review of current evidence","volume":"2014","author":"Voskoboynik","year":"2014","journal-title":"Biochem. Res. Int."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.010_bib0215","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"15","key":"10.1016\/j.biopha.2018.11.010_bib0220","first-page":"4595","article-title":"Phase I and pharmacokinetic study of Brequinar sodium (NSC 368390)","volume":"50","author":"Noe","year":"1990","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.biopha.2018.11.010_bib0225","first-page":"4648","article-title":"Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390)","volume":"49","author":"Arteaga","year":"1989","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.biopha.2018.11.010_bib0230","first-page":"4601","article-title":"Resistance of human melanoma cells against the cytotoxic and complement-enhancing activities of doxorubicin","volume":"47","author":"Panneerselvam","year":"1987","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.010_bib0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10637-006-9002-y","article-title":"A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma","volume":"25","author":"Smylie","year":"2007","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.biopha.2018.11.010_bib0240","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00008390-200304000-00015","article-title":"Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment","volume":"13","author":"Vorobiof","year":"2003","journal-title":"Melanoma Res."},{"issue":"27","key":"10.1016\/j.biopha.2018.11.010_bib0245","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1038\/onc.2013.313","article-title":"Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis","volume":"33","author":"He","year":"2014","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biopha.2018.11.010_bib0250","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.phymed.2013.09.002","article-title":"Berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 cells in culture and xenograft","volume":"21","author":"Mittal","year":"2014","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1158\/1535-7163.MCT-05-0199","article-title":"Benzodiazepinedione inhibitors of the Hdm2: p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo","volume":"5","author":"Koblish","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.010_bib0260","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","article-title":"Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0265","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)64722-0","article-title":"Expression of cdc2 and cyclin B1 in Helicobacter pylori-associated gastric MALT and MALT lymphoma: relationship to cell death, proliferation, and transformation","volume":"156","author":"Banerjee","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"22","key":"10.1016\/j.biopha.2018.11.010_bib0270","first-page":"6414","article-title":"Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma","volume":"62","author":"Hassan","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0275","first-page":"15","article-title":"Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses","volume":"150","author":"Kawamoto","year":"1997","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.010_bib0280","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ijc.11132","article-title":"Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer","volume":"105","author":"Rudolph","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"15","key":"10.1016\/j.biopha.2018.11.010_bib0285","first-page":"4000","article-title":"Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication","volume":"60","author":"Soria","year":"2000","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.010_bib0290","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF01269891","article-title":"Overexpression of cyclin B1 in human colorectal cancers","volume":"123","author":"Wang","year":"1997","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.010_bib0295","first-page":"44","article-title":"Expression profiling of cyclin B1 and D1 in cervical carcinoma","volume":"28","author":"Zhao","year":"2006","journal-title":"Exp. Oncol."},{"issue":"6518","key":"10.1016\/j.biopha.2018.11.010_bib0300","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/374131a0","article-title":"Principles of CDK regulation","volume":"374","author":"Morgan","year":"1995","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2018.11.010_bib0305","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2018.11.010_bib0310","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1002\/jcb.23296","article-title":"p21Cip1\/Waf1 protein and its function based on a subcellular localization [corrected]","volume":"112","author":"Cmielova","year":"2011","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.010_bib0315","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1368-7646(03)00044-X","article-title":"Differential effects of cell cycle regulatory protein p21(WAF1\/Cip1) on apoptosis and sensitivity to cancer chemotherapy","volume":"6","author":"Liu","year":"2003","journal-title":"Drug Resist. Updat."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218362085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218362085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T21:17:02Z","timestamp":1764105422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218362085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":63,"alternative-id":["S0753332218362085"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.11.010","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}